Treating end-stage heart failure is a considerable expense no matter what the treatment. Following the initial operation, costs for VAD-supported patients typically drop relative to those of transplant patients, who require high-priced pharmaceutical support for the transplanted heart.
Insurance coverage is dependent on many factors. Medicare and many insurance companies often pay for the Jarvik 2000. Please check with your insurance company to verify coverage.